Note: Single-source report; awaiting corroboration.
Neonatal opioid withdrawal syndrome (NOWS) affects newborns exposed to opioids during pregnancy, causing withdrawal symptoms after birth. The primary assessment methods for NOWS symptoms are the traditional Finnegan scoring system and the newer Eat, Sleep, Console (ESC) approach, which focuses on an infant’s ability to feed, sleep, and be consoled.
Historically, hospitals managed NOWS with a scheduled opioid taper, administering doses on a fixed schedule and gradually reducing them. An alternative method, symptom-based dosing, provides opioid medication based on an infant’s symptoms as needed, which may help minimize overtreatment.
An NIH-funded clinical trial across 23 U.S. hospitals, led by Dr. Lori Devlin and Dr. Leslie Young, compared symptom-based dosing and scheduled dosing. Among 383 infants assessed with ESC, those receiving symptom-based dosing were discharged about two and a half days earlier than those treated with scheduled dosing, and received fewer opioid doses. About two-thirds managed with symptom-based dosing avoided prolonged medication tapers, though some required switching to scheduled dosing to manage symptoms.
The outcomes, published in JAMA, suggest symptom-based dosing matches medication use to withdrawal severity and is as safe as scheduled tapering for infants, based on health outcomes up to three months of age.